Skip to main
IVVD

Invivyd Inc (IVVD) Stock Forecast & Price Target

Invivyd Inc (IVVD) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Invivyd is a biopharmaceutical company that is developing monoclonal antibody therapies to prevent and treat serious viral infectious diseases. The company's lead product, PEMGARDA, has received emergency use authorization from the U.S. FDA for the pre-exposure prevention of COVID-19 in immunocompromised individuals and is expected to see continued growth in sales. Invivyd also has promising next-generation antibody candidates, VYD2311 for COVID-19 and VBY329 for RSV infections, and a strong pipeline targeting other viral diseases like measles. With a positive outlook on the company's future success and proven track record of producing effective anti-SARS-CoV-2 antibodies, Invivyd's continued growth is expected and is a strong investment opportunity.

Bears say

Invivyd is focused on developing monoclonal antibodies for COVID-19 and other serious viral diseases, but with a lead mAb already approved and a longer-term mAb in development, their pipeline may be limited. Additionally, the company's reliance on one product for a significant portion of their revenue presents financial risk, especially in the unpredictable and competitive pharmaceutical industry. Finally, the company's relatively small size and lack of diversification make it susceptible to changes in market conditions and regulatory challenges.

Invivyd Inc (IVVD) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Invivyd Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Invivyd Inc (IVVD) Forecast

Analysts have given Invivyd Inc (IVVD) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Invivyd Inc (IVVD) has a Strong Buy consensus rating as of Jun 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Invivyd Inc (IVVD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.